Title
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
Author
Gezondheidsorganisatie TNO Gaubius Instituut TNO
de Knijff, P.
Stalenhoef, A.F.H.
Mol, M.J.T.M.
Gevers Leuven, J.A.
Smit, J.
Erkelens, D.W.
Schouten, J.
Frants, R.R.
Havekes, L.M.
Publication year
1990
Abstract
In a group of 120 patients with heterozygous familial hypercholesterolemia (FH) the influence of the apolipoprotein E (apoE) polymorphism on pre-treatment plasma lipid levels and on the response to treatment with simvastatin was studied. The apoE phenotype distribution did not differ significantly between the FH group and a sample group of the Dutch population. Differences in pre-treatment lipid levels were not related to the apoE polymorphism in this FH population. After 12 weeks use of a daily dose of 40 mg simvastatin, the plasma total cholesterol, low density lipoprotein (LDL)-cholesterol and plasma triglyceride levels were reduced on average by 33%, 38% and 19%, respectively. At the same time high density lipoprotein (HDL)-cholesterol concentration increased on average by 7%. In the combined FH patient group (males and females) a considerable interindividual variation in response to simvastatin was observed, we found that female FH patients with the apoE3E3 phenotype responded better on simvastatin treatment with respect to LDL-cholesterol than male FH patients with the apoE3E3 phenotype. Chemicals/CAS: Anticholesteremic Agents; Apolipoproteins E; Lovastatin, 75330-75-5; Simvastatin, 79902-63-9
Subject
apolipoprotein E
cholesterol
familial hypercholesterolemia
genetic polymorphism
simvastatin
apolipoprotein e
cholesterol
low density lipoprotein
simvastatin
triacylglycerol
article
familial hypercholesterolemia
human
major clinical study
oral drug administration
priority journal
Adult
Aged
Anticholesteremic Agents
Apolipoproteins E
Female
Heterozygote
Human
Hypercholesterolemia, Familial
Lovastatin
Male
Middle Age
Phenotype
Polymorphism (Genetics)
Sex Factors
Simvastatin
Support, Non-U.S. Gov't
To reference this document use:
http://resolver.tudelft.nl/uuid:3fe117dd-66db-4a16-b519-5691d5f9612f
DOI
https://doi.org/10.1016/0021-9150(90)90134-5
TNO identifier
231191
ISSN
0021-9150
Source
Atherosclerosis, 83 (83), 89-97
Document type
article